Frank  Torti net worth and biography

Frank Torti Biography and Net Worth

Director of Immunovant
Frank Torti, M.D., has served as Chairperson of our board of directors since June 2019 and Executive Chairperson since August 2021. Dr. Torti has served as the Vant Chair of RSI since January 2020. In this capacity he serves as Chairperson of the boards of directors of the biopharmaceutical companies in the Roivant family and is responsible for the operations and management of those companies. He previously served as Vant Investment Chair of RSI, from August 2018 to December 2019. Prior to joining RSI, from August 2007 to August 2018, Dr. Torti served as a Partner of New Enterprise Associates, or NEA, specializing in investments in healthcare. Prior to joining NEA, Dr. Torti worked for the Duke University Center for Clinical & Genetic Economics from 2002 to 2005 in various capacities, where he was involved in clinical trials research and economic evaluations of multinational clinical trials. Dr. Torti presently serves as Chairperson of the boards of directors of Arbutus Biopharma Corp. and several private biopharmaceutical companies. Dr. Torti served on the boards of directors of Urovant Sciences Ltd., from August 2018 to December 2019, and Myovant Sciences Ltd., from November 2018 to December 2019. During the course of his career, he has served on the boards of directors of numerous development and commercial stage public and private healthcare companies. Dr. Torti earned an M.D. from the University of North Carolina School of Medicine, an M.B.A. from Harvard Business School and a B.A. from the University of North Carolina.

What is Frank Torti's net worth?

The estimated net worth of Frank Torti is at least $10.32 million as of September 29th, 2022. Dr. Torti owns 393,358 shares of Immunovant stock worth more than $10,317,780 as of November 21st. This net worth approximation does not reflect any other assets that Dr. Torti may own. Additionally, Dr. Torti receives a salary of $92,500.00 as Director at Immunovant. Learn More about Frank Torti's net worth.

How old is Frank Torti?

Dr. Torti is currently 45 years old. There are 6 older executives and no younger executives at Immunovant. The oldest executive at Immunovant is Dr. William L. Macias M.D., Ph.D., Chief Medical Officer, who is 65 years old. Learn More on Frank Torti's age.

What is Frank Torti's salary?

As the Director of Immunovant, Inc., Dr. Torti earns $92,500.00 per year. There are 4 executives that earn more than Dr. Torti. The highest earning executive at Immunovant is Dr. Peter Salzmann M.B.A., M.D., CEO & Director, who commands a salary of $1,020,000.00 per year. Learn More on Frank Torti's salary.

How do I contact Frank Torti?

The corporate mailing address for Dr. Torti and other Immunovant executives is 320 WEST 37TH STREET, NEW YORK NY, 10018. Immunovant can also be reached via phone at 917-580-3099 and via email at [email protected]. Learn More on Frank Torti's contact information.

Has Frank Torti been buying or selling shares of Immunovant?

Frank Torti has not been actively trading shares of Immunovant over the course of the past ninety days. Most recently, on Thursday, September 29th, Frank Torti bought 20,000 shares of Immunovant stock. The stock was acquired at an average cost of $5.81 per share, with a total value of $116,200.00. Following the completion of the transaction, the director now directly owns 393,358 shares of the company's stock, valued at $2,285,409.98. Learn More on Frank Torti's trading history.

Who are Immunovant's active insiders?

Immunovant's insider roster includes Peter . (), Eva Barnett (CFO), Julia Butchko (Insider), Michael Geffner (Chief Medical Officer), Douglas Hughes (Director), Mark Levine (Chief Legal Officer and Corporate Secretary), William Macias (Insider), George Migausky (Director), Atul Pande (Director), Peter Salzmann (CEO), Jay Stout (CTO), and Frank Torti (Director). Learn More on Immunovant's active insiders.

Are insiders buying or selling shares of Immunovant?

During the last twelve months, insiders at the sold shares 36 times. They sold a total of 204,388 shares worth more than $6,214,884.80. The most recent insider tranaction occured on October, 23rd when insider Mark S Levine sold 4,361 shares worth more than $128,780.33. Insiders at Immunovant own 5.9% of the company. Learn More about insider trades at Immunovant.

Information on this page was last updated on 10/23/2024.

Frank Torti Insider Trading History at Immunovant

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/29/2022Buy20,000$5.81$116,200.00393,358View SEC Filing Icon  
See Full Table

Frank Torti Buying and Selling Activity at Immunovant

This chart shows Frank Torti's buying and selling at Immunovant by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Immunovant Company Overview

Immunovant logo
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.
Read More

Today's Range

Now: $26.23
Low: $25.90
High: $26.47

50 Day Range

MA: $29.18
Low: $25.22
High: $31.42

2 Week Range

Now: $26.23
Low: $24.61
High: $45.58

Volume

137,031 shs

Average Volume

1,078,453 shs

Market Capitalization

$3.85 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.66